Guardant Health has unveiled new data demonstrating that its multi-cancer assay has the ability to detect many early-stage cancers with high accuracy.

According to the data, which was presented at the American Association for Cancer Research Annual Meeting, the investigational next-generation Guardant SHIELD assay showed its ability to accurately detect four cancer types including colorectal, lung, pancreatic, and bladder.

In addition, the assay demonstrated high accuracy in detecting the tumour tissue of origin.

The data showed that the blood test obtained 90% sensitivity in detecting colorectal cancer (CRC) and 87% in lung cancer during stages I and II.

The Guardant SHIELD assay also demonstrated sensitivity of 93% for CRC and 93% for lung cancer for more advanced cancer stages III and IV.

The test achieved 73% sensitivity for pancreatic cancer and 52% for bladder cancer in stages I and II.

Guardant Health co-CEO AmirAli Talasaz said: “These positive results show that the next-generation Guardant SHIELD multi-cancer assay provides sensitive detection of early-stage cancers with the ability to identify the tumour tissue of origin with high accuracy.

“Presentation of these positive results represents a major step forward in our commitment to offering clinicians and patients a highly sensitive blood-based multi-cancer screening test in select tumor types where we believe cancer screening can save lives.”

The assay was also able to detect the tumor tissue of origin in 99% of colorectal, 94% of lung, 88% of bladder, and 86% of pancreatic cancers.

The Guardant SHIELD assay helps in the analysis of nearly 20,000 epigenomic biomarkers that provide information to identify a broad range of solid tumours in a single blood test.

In January this year, the company began the observational, prospective, multi-center SHIELD Lung study to enrol individuals who are being screened for several cancer types.

The study will enrol approximately 10,000 individuals who are eligible for lung cancer screening in the first cohort to evaluate Guardant SHIELD test’s ability in identifying lung cancer in high-risk individuals aged 50 to 80 years.